Lantern Pharma, Inc. (LTRN)
3.32
-0.06
(-1.78%)
USD |
NASDAQ |
May 27, 16:00
3.32
0.00 (0.00%)
After-Hours: 19:37
Lantern Pharma Cash from Financing (Quarterly) : 0.00 for March 31, 2026
Cash from Financing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (Quarterly) Benchmarks
| BioVie, Inc. | 0.00 |
| Vertex Pharmaceuticals, Inc. | -538.80M |
| Spero Therapeutics, Inc. | 0.00 |
| Replimune Group, Inc. | 10.45M |
| Acurx Pharmaceuticals, Inc. | 3.106M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -3.773M |
| Cash from Investing (Quarterly) | 4.25M |
| Free Cash Flow | -15.07M |
| Free Cash Flow Per Share (Quarterly) | -0.3353 |
| Free Cash Flow to Equity (Quarterly) | -3.753M |
| Free Cash Flow to Firm (Quarterly) | -3.773M |
| Free Cash Flow Yield | -41.16% |